Adverse Cardiovascular Disease

Zeposia demonstrated a low incidence of treatment-related cardiac adverse events for patients with ulcerative colitis or multiple sclerosis, according to a presenter at the Congress of the European Crohn’s and Colitis Organization.

AstraZeneca has been granted fast track designation in the U.S. for the development of Lokelma, according to a company press release.

Among patients with rheumatoid arthritis, 30 days of glucocorticoid use in 6 months is associated with 15% increased odds of major adverse cardiac events in the next 6 months, according to data presented at ACR Convergence 2021.